Stage 3 lung cancer is serious but not hopeless. The five-year relative survival rate for lung cancer that has spread to nearby lymph nodes (regional stage) is 38.2%, according to the most recent federal cancer data. That number has improved significantly over the past decade, largely because of newer treatments that weren’t available even five years ago. What “stage 3” means for any individual person varies widely depending on the sub-stage, the type of lung cancer, whether surgery is possible, and how the body responds to treatment.
What Stage 3 Actually Means
Stage 3 lung cancer sits between localized disease (stages 1 and 2, where the cancer is confined to the lung or nearby tissue) and metastatic disease (stage 4, where it has spread to distant organs like the brain, bones, or liver). In stage 3, the tumor has grown large enough or spread enough to involve lymph nodes in the chest, but it has not traveled to distant parts of the body. That distinction matters because it keeps certain treatments, including surgery and high-dose radiation aimed at a cure, on the table for many patients.
How 3A, 3B, and 3C Differ
Stage 3 is split into three sub-stages, and the differences between them are significant. The sub-stage is determined by the size and location of the tumor and which lymph nodes are involved.
Stage 3A is generally the most treatable. The tumor may be large or may have grown into nearby structures, but the lymph node involvement is more limited. Stage 3A is usually classified as surgically resectable, meaning a surgeon can potentially remove all visible cancer. Patients who are fit enough typically have surgery to remove part or all of the affected lung, combined with chemotherapy and radiation.
Stage 3B involves more extensive lymph node spread. Whether surgery is an option depends on specific factors: how many lymph node stations are involved, whether the nodes are bulky (generally over 2.5 to 3 cm), and whether cancer has grown into the nodes rather than just sitting nearby. Single-station lymph node involvement is often still resectable. Multi-station or bulky involvement usually is not.
Stage 3C represents the most advanced form of stage 3. The tumor is large and has spread to lymph nodes on the opposite side of the chest or above the collarbone. Stage 3C is classified as unresectable in most cases. Treatment focuses on chemotherapy combined with radiation rather than surgery.
What Treatment Typically Looks Like
For patients whose tumors can be surgically removed, treatment usually involves a combination of surgery, chemotherapy, and sometimes radiation. The surgery itself removes part of the lung (lobectomy) or the entire lung (pneumonectomy), and chemotherapy is given either before or after surgery to target any remaining cancer cells.
For patients whose stage 3 cancer cannot be surgically removed, the standard approach is concurrent chemoradiation: chemotherapy and radiation delivered at the same time. This combination provides better survival outcomes than giving them one after the other, though it also causes more side effects, including fatigue, difficulty swallowing, and irritation of the esophagus and lungs.
The biggest recent advance for unresectable stage 3 lung cancer is consolidation immunotherapy. After completing chemoradiation, patients whose cancer hasn’t progressed receive an immunotherapy drug for up to 12 months. This treatment works by blocking a protein that tumors use to hide from the immune system, essentially removing the cancer’s camouflage so the body’s own defenses can attack it. In the landmark PACIFIC trial, which enrolled 713 patients with stage 3 disease, 42.9% of patients who received this immunotherapy after chemoradiation were still alive at five years, compared to 33.4% of those who received a placebo. That roughly 10-percentage-point improvement represents one of the most meaningful survival gains in stage 3 lung cancer treatment in recent years.
Symptoms at Stage 3
By stage 3, most people are experiencing noticeable symptoms. The most common include a persistent cough that worsens over time, chest pain that gets sharper with deep breathing or coughing, shortness of breath, and fatigue. Some patients cough up blood or rust-colored mucus. When the tumor presses on certain nerves or structures in the chest, it can cause hoarseness, arm or shoulder pain, swelling of the neck and face, or wheezing.
Recurring lung infections like pneumonia or bronchitis that keep coming back or won’t fully clear are another hallmark. Weight loss and loss of appetite are common as the body diverts energy to fighting the disease. Some people notice clubbing, a widening and rounding of the fingertips and nail beds, which results from chronically low oxygen levels.
Recurrence Risk After Treatment
Even after successful treatment, stage 3 lung cancer carries a substantial risk of coming back. Five-year recurrence rates after surgery with curative intent are around 57% for stage 3 patients. That means slightly more than half of patients who undergo surgery will see their cancer return within five years. Recurrence can happen locally (in the chest) or in distant organs.
Because of this high recurrence risk, follow-up after treatment is intensive. Patients typically undergo regular imaging scans and check-ups for several years, with the schedule gradually spacing out over time if no recurrence is detected. The addition of immunotherapy after chemoradiation has helped reduce recurrence, but the risk remains a central reality of stage 3 disease.
Small Cell vs. Non-Small Cell at Stage 3
The numbers above primarily apply to non-small cell lung cancer (NSCLC), which accounts for roughly 80 to 85% of lung cancers. Small cell lung cancer (SCLC) at a similar stage, called limited-stage disease, carries a worse prognosis. Median survival for limited-stage SCLC is 16 to 24 months, and the five-year survival rate is about 14%. Small cell lung cancer grows and spreads faster, which is why it is staged and treated differently, typically with chemotherapy and radiation rather than surgery.
What Shapes an Individual Outlook
Population-level survival statistics are averages drawn from thousands of patients, including those diagnosed years ago with older treatments. Several factors push individual outcomes above or below that average. Younger patients and those in better overall health tend to do better because they can tolerate more aggressive treatment. Whether the cancer responds to initial chemoradiation matters enormously, since responding well opens the door to consolidation immunotherapy. Tumor biology plays a role too: certain genetic mutations and protein expressions make cancers more vulnerable to targeted therapies or immunotherapy.
The sub-stage itself is one of the strongest predictors. A patient with resectable stage 3A disease who undergoes surgery and completes follow-up treatment has meaningfully better odds than a patient with stage 3C disease that cannot be surgically removed. The 38.2% five-year survival figure for regional lung cancer is a blend of all these scenarios. For patients who respond well to modern treatment combinations, including immunotherapy, five-year survival can exceed 40%.